Thursday, September 29, 2022


Biotechnology News Magazine

Alliance Pharma Executive Team Grows by Four, Supporting Bioanalytical and CMC Testing Expansions

Latest Posts

City of Hope to Accelerate Immunotherapy Research & Treatment Innovation with $15 Mil Gift from Ted Schwartz Family

Ted Schwartz, who is now cancer free, achieved complete remission at City of Hope in 2020 with the center's leading CAR T cell therapy after a 16-year battle with lymphoma, provided the gift to City of Hope to advance treatment options that offer better outcomes and quality of life for people living with cancer.

Neurocrine Biosciences Appoints Dr Ingrid Delaet as Chief Regulatory Officer

Prior to joining Neurocrine Biosciences, Dr Ingrid Delaet served as Senior Vice President, Regulatory Affairs at Intercept Pharmaceuticals, which she joined in 2016.

Astrea Bioseparations Introduces Nereus LentiHERO, a Fit-for-purpose Solution for Lentiviral Vector Purification

“We believe that AstreAdept will be a game-changer,” explained Astrea Bioseparations’ CEO Terry Pizzie. “Our approach was to rapidly develop and incorporate this material into the Nereus LentiHERO, a simple, fit-for-purpose device that radically transforms how lentivirus can be purified [in terms of speed, recovery, and efficiency].

At Pack Expo, Schreiner MediPharm to Debut Functional Labels Designed from More Sustainable Materials

Schreiner MediPharm advises he new label concepts are based on existing items in Schreiner MediPharm’s roster of functional labeling solutions.

Alliance Pharma (Alliance), a global leader in bioanalytical, DMPK and CMC testing services in the pharmaceutical and biopharmaceutical industry, has grown their leadership team by four, bringing on board a new Chief Operating Officer (COO), Chief Commercial Officer (CCO), Chief Financial Officer (CFO), and Chief People Officer (CPO).

CRO Alliance Pharma’s Executive Team Grows by Four, Supporting Bioanalytical and CMC Testing Expansions

These leaders will support continued global expansion, which includes Alliance’s recent acquisition of U.K.-based Drug Development Solutions (DDS) from LGC and new bioanalytical laboratory opening in Australia in November.

Jean Pierre (JP) Boutrand, DVM, M.S., COO, is leading Alliance’s global operational strategy in the preclinical, clinical bioanalysis, and CMC business lines. He has more than 25 years of executive operation, commercial, and corporate experience in life sciences laboratory operations, digital technologies, medical device innovation, and pharmaceutical development, as well as designing and implementing improvements for effective teams and customer satisfaction.

Vito Saccente is Alliance’s new CCO, bringing 25+ years of sales leadership experience in the life sciences CRO industry, including all aspects of nonclinical and clinical testing for vaccines, small molecules, and large molecules. He also has experience in supporting formulation development, manufacturing, and analytical testing of pharmaceutical products, along with contributing to corporate strategy for mergers and acquisitions. At Alliance, Saccente will be focused on the global restructuring of the commercial process and organization structure, activities that will further improve the customer experience.

Glenn Weber, CFO, has over 35 years’ experience in corporate finance across multiple industries. His early career included financial analysis and corporate development in the tire industry, followed by the global chemical industry. Most recently, Weber was CFO of several private equity-sponsored companies.

Susan Woolley, CPO, is driving employee-centric initiatives that optimize Alliance Pharma’s success through development programs and engagement. She has 20 years of experience in change management, succession planning, talent development, coaching leaders, improving synergy and effectiveness, and inspiring results across all levels of an organization.

“These leaders bring years of specialized expertise and leadership for our team and our scientists,” said Alliance CEO Patrick Bennett. “Alliance is growing rapidly, and these experienced leaders ensure continued growth and support for our customers’ drug discovery and development programs.”

Latest Posts

Learn More




Our Sister Publication

Medical Device News Magazine